AN2 Therapeutics, Inc.
NASDAQ:ANTX
1.255 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Assets: | |||||
Current Assets: | |||||
Cash & Cash Equivalents
| 15.647 | 27.219 | 12.097 | 4.07 | 5.598 |
Short Term Investments
| 91.648 | 68.84 | 46.458 | 0 | 0 |
Cash and Short Term Investments
| 107.295 | 96.059 | 58.555 | 4.07 | 5.598 |
Net Receivables
| 0 | 0 | 0 | 0 | 0 |
Inventory
| 0 | 0 | 0 | 0 | 0 |
Other Current Assets
| 3.212 | 2.562 | 1.551 | 0.164 | 0.102 |
Total Current Assets
| 110.507 | 98.621 | 60.106 | 4.234 | 5.7 |
Non-Current Assets: | |||||
Property, Plant & Equipment, Net
| 0 | 0.053 | 0 | 0 | 0 |
Goodwill
| 0 | 0 | 0 | 0 | 0 |
Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
Long Term Investments
| 27.194 | 3.219 | 3.486 | 0 | 0 |
Tax Assets
| 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets
| 1.043 | 0.667 | 1.724 | 0 | 0 |
Total Non-Current Assets
| 28.237 | 3.939 | 5.21 | 0 | 0 |
Total Assets
| 138.744 | 102.56 | 65.316 | 4.234 | 5.7 |
Liabilities & Equity: | |||||
Current Liabilities: | |||||
Account Payables
| 2.676 | 2.122 | 1.063 | 0.132 | 0.051 |
Short Term Debt
| 0 | 0.106 | 0 | 0 | 0 |
Tax Payables
| 0 | 0 | 0 | 0 | 0 |
Deferred Revenue
| 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities
| 11.367 | 4.958 | 2.332 | 1.327 | 0.108 |
Total Current Liabilities
| 14.043 | 7.186 | 3.395 | 1.459 | 0.159 |
Non-Current Liabilities: | |||||
Long Term Debt
| 0 | 0 | 0 | 0 | 0.728 |
Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities
| 0 | 0.002 | 109.332 | 23.094 | 0 |
Total Non-Current Liabilities
| 0 | 0.002 | 109.332 | 23.094 | 0.728 |
Total Liabilities
| 14.043 | 7.188 | 112.727 | 24.553 | 0.887 |
Equity: | |||||
Preferred Stock
| 0 | 102.56 | 109.319 | 23.07 | 10.614 |
Common Stock
| 0 | 0 | 0 | 0 | 0 |
Retained Earnings
| -154.455 | -89.723 | -47.384 | -20.319 | -5.801 |
Accumulated Other Comprehensive Income/Loss
| 0.275 | -0.374 | -0.027 | 0 | 0 |
Other Total Stockholders Equity
| 278.881 | 185.469 | 0 | -23.07 | 0 |
Total Shareholders Equity
| 124.701 | 95.372 | -47.411 | -20.319 | 4.813 |
Total Equity
| 124.701 | 95.372 | -47.411 | -20.319 | 4.813 |
Total Liabilities & Shareholders Equity
| 138.744 | 102.56 | 65.316 | 4.234 | 5.7 |